TAK GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Takeda Pharmaceutical Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Values in USD · ADR · Reports in JPY
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Current Price
$16.68
+0.60%GoodMoat Value
$44.87
169.0% undervaluedProfile
Valuation (TTM)
Market Cap$52.11B
P/E73.27
EV—
P/B1.12
Shares Out3.12B
P/Sales1.75
Revenue$29.80B
EV/EBITDA9.47
Takeda Pharmaceutical Company (TAK) Quality Analysis
TAK Profitability
Profitability trend analysis coming soon
TAK Growth
Growth trend analysis coming soon
TAK Financial Health
Financial health indicators coming soon
TAK Quality & Fundamental Analysis
Takeda Pharmaceutical Company (TAK) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NYSE. This quality analysis page evaluates Takeda Pharmaceutical Company's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Takeda Pharmaceutical Company has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 2.53% and a return on equity (ROE) of 1.62%. Return on assets (ROA) stands at 0.79%.
The debt-to-equity ratio is 0.76, with a current ratio of 1.01. Operating margin is 7.48%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Takeda Pharmaceutical Company is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.